Chronic Obstructive Pulmonary Disease Drugs Market

Chronic obstructive pulmonary disease ( COPD ) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs.

Chronic Obstructive Pulmonary Disease Drugs Market contains market size and forecasts of Chronic Obstructive Pulmonary Disease Drugs in global, including the following market information:

Global Chronic Obstructive Pulmonary Disease Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Chronic Obstructive Pulmonary Disease Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Chronic Obstructive Pulmonary Disease Drugs companies in 2021 (%)

The global Chronic Obstructive Pulmonary Disease Drugs market was valued at 23570 million in 2021 and is projected to reach US$ 32630 million by 2028, at a CAGR of 4.8% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Inhalers Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chronic Obstructive Pulmonary Disease Drugs include AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva Pharmaceuticals, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals and Ario Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

Wesurveyed the Chronic Obstructive Pulmonary Disease Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chronic Obstructive Pulmonary Disease Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Chronic Obstructive Pulmonary Disease Drugs Market Segment Percentages, by Type, 2021 (%)

Inhalers

Nebulizers

Global Chronic Obstructive Pulmonary Disease Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Chronic Obstructive Pulmonary Disease Drugs Market Segment Percentages, by Application, 2021 (%)

Emphysema

Chronic Bronchitis

Refractory Asthma

Others

Global Chronic Obstructive Pulmonary Disease Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Chronic Obstructive Pulmonary Disease Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chronic Obstructive Pulmonary Disease Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Chronic Obstructive Pulmonary Disease Drugs revenues share in global market, 2021 (%)

Key companies Chronic Obstructive Pulmonary Disease Drugs sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Chronic Obstructive Pulmonary Disease Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AstraZeneca

Boehringer Ingelheim

GSK

Novartis

Teva Pharmaceuticals

Ache Laboratorios Farmaceuticos

Almirall

Aquinox Pharmaceuticals

Ario Pharma

Asmacure

Astellas Pharma

BioMarck Pharmaceuticals